Xilio Therapeutics, Inc.

NASDAQ:XLO

Biotechnology

Healthcare
$7.63 +5.14%

+$0.45 today

Market cap
$53.90M
Beta
-0.09
P/E (TTM)
-48.1
EPS (TTM)
-$0.19
52W Low $6.47High $12.74

Volume 0.01M

Average 0.05M

XLO Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Xilio Therapeutics, Inc.NASDAQ: XLO

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin dips below year-ago levels

Q1 FY2026 selling, general & admin of $6.58M fell 22.7% year over year, behind the +2.3% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 11.0% from the prior quarter. Over 3 fiscal years it compounded at -0.3% a year.

Context

  • Selling, general & admin amounted to 67.9% of revenue in FY2025, down 322.7 pp from a year earlier.
  • Selling, general & admin increased in 1 of the last 3 fiscal years.

What to watch

Whether selling, general & admin reaches the consensus estimate from 1 analysts of $64.72M (+117.8%) for the fiscal year ending Dec 2026, a step up from the +19.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$6.58M-11.0% QoQ
Last fiscal yearDec 2025
$29.71M+19.9% YoY
LTMMar 2026
$27.78M+2.3% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-22.7%+171.0%+193.7 pp
1 year+19.9%+117.8%+97.9 pp
3-year CAGR-0.3%-28.4%-28.1 pp
5-year CAGR-23.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
29.71M USD
Year-over-year change
+19.9%
4-year CAGR
+7.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How XLO compares with its peers on the latest reported figures

  • XLO's LTM Mar 2026 selling, general & admin of $27.78M is the 2nd highest of the 4 companies compared; the peer median is $14.61M.
  • Its year-over-year change of +2.3% is the 3rd highest of 4, against a peer median of +87.7%.
  • Selling, general & admin amounts to 51.9% of revenue for XLO, versus a peer median of 21.1%.
XLO Competitors Peer median
Selling, General & Admin for XLO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PDSBPDS Biotechnology CorporationLTM Mar 2026$3.07B +22461.6%+0.7%—
XLOXilio Therapeutics, Inc.LTM Mar 2026$27.78M +2.3%-0.3%51.9%
OKUROnKure Therapeutics, Inc.LTM Mar 2026$14.61M +87.7%+55.5%—
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$7.41M -56.6%+8.2%21.1%
Peer median (excluding XLO) $14.61M+87.7%+8.2%21.1%

Competitors are the stored peer set for XLO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0006.34M43.77M
Cost of Revenue1.5M0001.54M
Gross Profit(1.5M)006.34M42.23M
Gross Margin———100.0%96.5%
Research & Development51.19M59.2M52.14M41.21M56.04M
Selling, General & Admin22.36M29.95M27M24.78M29.71M
Operating Expenses73.55M89.15M79.13M66.93M84.21M
Depreciation & Amortization1.5M1.85M1.9M1.64M1.54M
EBITDA(73.7M)(86.38M)(74.5M)(58M)(33.5M)
EBITDA Margin———-914.3%-76.5%
Operating Income(75.04M)(89.15M)(79.13M)(60.58M)(41.98M)
Operating Margin———-954.9%-95.9%
Interest Income6000003.4M
Interest Expense600K00100K0
Other Income / Expenses(756K)927K2.73M2.34M6.95M
Income Before Tax(75.8M)(88.22M)(76.4M)(58.24M)(35.04M)
Pre-Tax Margin———-918.0%-80.1%
Income Tax Expense00000
Net Income(75.8M)(88.22M)(76.4M)(58.24M)(35.04M)
Net Margin———-918.0%-80.1%
EPS (Basic)(189.28)(45.08)(38.92)(15.26)(4.19)
EPS (Diluted)(189.28)(45.08)(38.92)(15.26)(4.19)
Weighted Avg Shares400.45K1.96M1.96M3.82M83.59M
Weighted Avg Shares (Diluted)400.45K1.96M1.96M3.82M83.59M

Xilio Therapeutics, Inc.

NASDAQ:XLO

Intrinsic Alpha fair value

Locked

Current Price

$7.63

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.